Accelerating Synthetic & Phytocannabinoid Research & Development into Clinical Approvals for Neurological Obesity, Pain, Inflammatory Indications & More
At a time when you were struggling to navigate complex scientific, regulatory, and commercial challenges to bring safe, effective cannabinoid-based medicines to patients in need, the 8th Cannabinoid & Endocannabinoid Drug Development Summit uniquely brought together 60+ leading experts from preclinical research, clinical trials, pharmacology, regulatory affairs, and intellectual property - offering a comprehensive, multidisciplinary platform.
Covering diverse therapeutic areas, from neurology and inflammation to endometriosis, attendees joined to engage in critical discussions, forge strategic partnerships, and gain the knowledge needed to overcome key hurdles in clinical development.
This was the time to connect, collaborate, and drive forward the next generation of clinically validated cannabinoid therapies with pioneering experts from Ananda, Synendos, Indication BioSciences, Nalu Bio and more.
2025 Speakers
2025 Attending Companies Included